Related Experiment Video
Updated: Nov 10, 2025
Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
miR-26a attenuates colitis and colitis-associated cancer by targeting the multiple intestinal inflammatory pathways
Wei Zhang1, Xianghui Fu2,3, Jiansheng Xie1
1Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, 3 East Qingchun Road, Hangzhou, Zhejiang 310016, China.
Abstract:
Patients with inflammatory bowel disease are at increased risk for colitis-associated colorectal cancer (CAC). Therefore, controlling intestinal inflammation is a key therapeutic strategy for CAC. MicroRNAs (miRNAs or miRs) are a family of small noncoding RNAs that have the capacity to regulate fundamental biological processes. To date, a number of miRNAs have been identified as critical regulators of inflammation. However, the specific role of miR-26a in colonic inflammation and colitis-associated carcinogenesis is still elusive. Here, we generated mice with miR-26a myeloid-cell-specific overexpression to show that miR-26a suppressed the intestinal inflammatory response in macrophages by decreasing nuclear factor κB (NF-κB)/STAT3 activation and interleukin 6 (IL-6) production. At the molecular level, a number of NF-κB regulators, including TLR3, PTEN, and PKCδ, were identified as potential targets of miR-26a. Our results thus identify a novel miRNA-mediated mechanism that suppresses carcinogenic inflammation in the colon.
Insights
MicroRNA-26a (miR-26a) suppresses intestinal inflammation and colitis-associated cancer by inhibiting key inflammatory pathways in macrophages. This discovery offers a potential new therapeutic strategy for colorectal cancer.
Area of Science:
- Molecular Biology
- Immunology
- Oncology
Background:
- Inflammatory bowel disease (IBD) patients face elevated risks for colitis-associated colorectal cancer (CAC).
- Targeting intestinal inflammation is crucial for effective CAC therapeutic strategies.
- MicroRNAs (miRNAs) are regulators of biological processes, with some identified as critical inflammation modulators.
Purpose of the Study:
- To investigate the role of microRNA-26a (miR-26a) in colonic inflammation and colitis-associated carcinogenesis.
- To elucidate the molecular mechanisms by which miR-26a influences inflammatory responses in the colon.
Main Methods:
- Generated mice with myeloid-cell-specific overexpression of miR-26a.
- Assessed the impact of miR-26a on intestinal inflammatory responses in macrophages.
- Analyzed the modulation of nuclear factor κB (NF-κB)/STAT3 activation and interleukin 6 (IL-6) production.
- Identified potential miR-26a molecular targets, including TLR3, PTEN, and PKCδ.
Main Results:
- Myeloid-specific miR-26a overexpression suppressed intestinal inflammatory responses.
- miR-26a decreased NF-κB/STAT3 activation and IL-6 production in macrophages.
- TLR3, PTEN, and PKCδ were identified as potential direct targets of miR-26a.
Conclusions:
- miR-26a acts as a suppressor of colonic inflammation and associated carcinogenesis.
- This study identifies a novel miRNA-mediated mechanism for controlling inflammatory responses in the colon.
- miR-26a represents a potential therapeutic target for managing colitis-associated colorectal cancer.
More Related Videos
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
01:22MicroRNAs
01:22MicroRNAs